第一单位：
Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Avenida de Pio XII, 55, 31008 Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
作者：
Iñaki,Etxeberria [1]
;
Elixabet,Bolaños [2]
;
Jose I,Quetglas [3]
;
Alena,Gros [4]
;
Alberto,Villanueva [5]
;
Jara,Palomero [4]
;
Alfonso R,Sánchez-Paulete [3]
;
Jose María,Piulats [6]
;
Xavier,Matias-Guiu [7]
;
Irene,Olivera [1]
;
Maria C,Ochoa [1]
;
Sara,Labiano [3]
;
Saray,Garasa [3]
;
Inmaculada,Rodriguez [1]
;
August,Vidal [8]
;
Uxua,Mancheño [3]
;
Sandra,Hervás-Stubbs [3]
;
Arantza,Azpilikueta [1]
;
Itziar,Otano [3]
;
M Angela,Aznar [3]
;
Miguel F,Sanmamed [9]
;
Susana,Inogés [10]
;
Pedro,Berraondo [1]
;
Álvaro,Teijeira [1]
;
Ignacio,Melero [11]
作者单位：
Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Avenida de Pio XII, 55, 31008 Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
[1]
Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Avenida de Pio XII, 55, 31008 Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.
[2]
Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Avenida de Pio XII, 55, 31008 Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
[3]
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Vall d'Hebron Institute of Oncology (V.H.I.O.), Barcelona, Spain.
[4]
Program against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, L'hospitalet del Llobregat, Barcelona, Spain.
[5]
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Program against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology, L'hospitalet del Llobregat, Barcelona, Spain; Department of Medical Oncology, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.
[6]
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Department of Pathology Hospital Universitari Arnau de Vilanova, University of Lleida, IRB-Lleida, Lleida, Spain; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain.
[7]
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain.
[8]
Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Avenida de Pio XII, 55, 31008 Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
[9]
Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.
[10]
Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Avenida de Pio XII, 55, 31008 Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. Electronic address: imelero@unav.es.
[11]
主题词
过继转移(Adoptive Transfer);动物(Animals);抗体, 单克隆(Antibodies, Monoclonal);CD8阳性T淋巴细胞(CD8-Positive T-Lymphocytes);细胞系, 肿瘤(Cell Line, Tumor);树突细胞(Dendritic Cells);人类(Humans);免疫疗法, 过继(Immunotherapy, Adoptive);白细胞介素12(Interleukin-12);淋巴细胞, 肿瘤浸润(Lymphocytes, Tumor-Infiltrating);黑色素瘤, 实验性(Melanoma, Experimental);小鼠(Mice);T淋巴细胞, 细胞毒性(T-Lymphocytes, Cytotoxic)
DOI
10.1016/j.ccell.2019.10.006
PMID
31761658
发布时间
2020-05-27
换一批
换一批
